{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T23:25:43Z","timestamp":1772321143252,"version":"3.50.1"},"publisher-location":"New York, NY","reference-count":40,"publisher":"Springer US","isbn-type":[{"value":"9781071612040","type":"print"},{"value":"9781071612057","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-1-0716-1205-7_17","type":"book-chapter","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T12:03:16Z","timestamp":1615464196000},"page":"223-233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PD-L1 Detection on Circulating Melanoma Cells"],"prefix":"10.1007","author":[{"given":"Joseph W.","family":"Po","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bavanthi","family":"Balakrishnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Brungs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Saricilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Therese M.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"17_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lungcan.2019.06.021","volume":"134","author":"PN Ding","year":"2019","unstructured":"Ding PN, Becker TM, Bray VJ, Chua W, Ma YF, Lynch D, Po J, Luk AWS, Caixeiro N, de Souza P, Roberts TL (2019) The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a prospective study. Lung Cancer 134:187\u2013193. https:\/\/doi.org\/10.1016\/j.lungcan.2019.06.021","journal-title":"Lung Cancer"},{"issue":"3","key":"17_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/mi9030100","volume":"9","author":"M Lim","year":"2018","unstructured":"Lim M, Kim CJ, Sunkara V, Kim MH, Cho YK (2018) Liquid biopsy in lung cancer: clinical applications of circulating biomarkers (CTCs and ctDNA). Micromachines (Basel) 9(3):100. https:\/\/doi.org\/10.3390\/mi9030100","journal-title":"Micromachines (Basel)"},{"issue":"5","key":"17_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","volume":"6","author":"C Alix-Panabieres","year":"2016","unstructured":"Alix-Panabieres C, Pantel K (2016) Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6(5):479\u2013491. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1483","journal-title":"Cancer Discov"},{"issue":"11","key":"17_CR4","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1002\/ijc.28516","volume":"134","author":"TM Becker","year":"2014","unstructured":"Becker TM, Caixeiro NJ, Lim SH, Tognela A, Kienzle N, Scott KF, Spring KJ, de Souza P (2014) New frontiers in circulating tumor cell analysis: a reference guide for biomolecular profiling toward translational clinical use. Int J Cancer 134(11):2523\u20132533. https:\/\/doi.org\/10.1002\/ijc.28516","journal-title":"Int J Cancer"},{"key":"17_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.addr.2018.01.003","volume":"125","author":"WL Hwang","year":"2018","unstructured":"Hwang WL, Pleskow HM, Miyamoto DT (2018) Molecular analysis of circulating tumors cells: biomarkers beyond enumeration. Adv Drug Deliv Rev 125:122\u2013131. https:\/\/doi.org\/10.1016\/j.addr.2018.01.003","journal-title":"Adv Drug Deliv Rev"},{"key":"17_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12885-016-2578-5","volume":"16","author":"S Zhang","year":"2016","unstructured":"Zhang S, Li L, Wang T, Bian L, Hu H, Xu C, Liu B, Liu Y, Cristofanilli M, Jiang Z (2016) Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. BMC Cancer 16:526. https:\/\/doi.org\/10.1186\/s12885-016-2578-5","journal-title":"BMC Cancer"},{"issue":"39","key":"17_CR7","doi-asserted-by":"publisher","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"ES Gray","year":"2015","unstructured":"Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA, Siew K, Lomma C, Cooper A, Khattak MA, Meniawy TM, Long GV, Carlino MS, Millward M, Ziman M (2015) Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 6(39):42008\u201342018. https:\/\/doi.org\/10.18632\/oncotarget.5788","journal-title":"Oncotarget"},{"issue":"2","key":"17_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ygyno.2017.02.042","volume":"145","author":"M Lee","year":"2017","unstructured":"Lee M, Kim EJ, Cho Y, Kim S, Chung HH, Park NH, Song YS (2017) Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer. Gynecol Oncol 145(2):361\u2013365. https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.042","journal-title":"Gynecol Oncol"},{"issue":"12","key":"17_CR9","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.1158\/0008-5472.CAN-05-4198","volume":"66","author":"K Koyanagi","year":"2006","unstructured":"Koyanagi K, Mori T, O\u2019Day SJ, Martinez SR, Wang HJ, Hoon DS (2006) Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res 66(12):6111\u20136117. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4198","journal-title":"Cancer Res"},{"issue":"40","key":"17_CR10","doi-asserted-by":"publisher","first-page":"67355","DOI":"10.18632\/oncotarget.18641","volume":"8","author":"CA Aya-Bonilla","year":"2017","unstructured":"Aya-Bonilla CA, Marsavela G, Freeman JB, Lomma C, Frank MH, Khattak MA, Meniawy TM, Millward M, Warkiani ME, Gray ES, Ziman M (2017) Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. Oncotarget 8(40):67355\u201367368. https:\/\/doi.org\/10.18632\/oncotarget.18641","journal-title":"Oncotarget"},{"issue":"1","key":"17_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13045-019-0735-4","volume":"12","author":"P Banko","year":"2019","unstructured":"Banko P, Lee SY, Nagygyorgy V, Zrinyi M, Chae CH, Cho DH, Telekes A (2019) Technologies for circulating tumor cell separation from whole blood. J Hematol Oncol 12(1):48. https:\/\/doi.org\/10.1186\/s13045-019-0735-4","journal-title":"J Hematol Oncol"},{"issue":"1","key":"17_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1373\/clinchem.2012.194258","volume":"59","author":"C Alix-Panabieres","year":"2013","unstructured":"Alix-Panabieres C, Pantel K (2013) Circulating tumor cells: liquid biopsy of cancer. Clin Chem 59(1):110\u2013118. https:\/\/doi.org\/10.1373\/clinchem.2012.194258","journal-title":"Clin Chem"},{"issue":"6","key":"17_CR13","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1158\/0008-5472.CAN-13-1739","volume":"74","author":"A Satelli","year":"2014","unstructured":"Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S (2014) Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res 74(6):1645\u20131650. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1739","journal-title":"Cancer Res"},{"issue":"11","key":"17_CR14","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1158\/2159-8290.CD-14-0471","volume":"4","author":"JP Sullivan","year":"2014","unstructured":"Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor TT, Louis DN, Toner M, Maheswaran S, Haber DA (2014) Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov 4(11):1299\u20131309. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0471","journal-title":"Cancer Discov"},{"key":"17_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fmolb.2015.00076","volume":"2","author":"F Salvianti","year":"2015","unstructured":"Salvianti F, Orlando C, Massi D, De Giorgi V, Grazzini M, Pazzagli M, Pinzani P (2015) Tumor-related methylated cell-free DNA and circulating tumor cells in melanoma. Front Mol Biosci 2:76. https:\/\/doi.org\/10.3389\/fmolb.2015.00076","journal-title":"Front Mol Biosci"},{"issue":"3","key":"17_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/00000372-199406000-00003","volume":"16","author":"O Ben-Izhak","year":"1994","unstructured":"Ben-Izhak O, Stark P, Levy R, Bergman R, Lichtig C (1994) Epithelial markers in malignant melanoma. A study of primary lesions and their metastases. Am J Dermatopathol 16(3):241\u2013246. https:\/\/doi.org\/10.1097\/00000372-199406000-00003","journal-title":"Am J Dermatopathol"},{"issue":"6","key":"17_CR17","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","volume":"10","author":"TM Grzywa","year":"2017","unstructured":"Grzywa TM, Paskal W, Wlodarski PK (2017) Intratumor and intertumor heterogeneity in melanoma. Transl Oncol 10(6):956\u2013975. https:\/\/doi.org\/10.1016\/j.tranon.2017.09.007","journal-title":"Transl Oncol"},{"issue":"8","key":"17_CR18","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1038\/jid.2015.127","volume":"135","author":"ES Gray","year":"2015","unstructured":"Gray ES, Reid AL, Bowyer S, Calapre L, Siew K, Pearce R, Cowell L, Frank MH, Millward M, Ziman M (2015) Circulating melanoma cell subpopulations: their heterogeneity and differential responses to treatment. J Invest Dermatol 135(8):2040\u20132048. https:\/\/doi.org\/10.1038\/jid.2015.127","journal-title":"J Invest Dermatol"},{"issue":"9","key":"17_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11912-019-0827-x","volume":"21","author":"V Vanella","year":"2019","unstructured":"Vanella V, Festino L, Trojaniello C, Vitale MG, Sorrentino A, Paone M, Ascierto PA (2019) The role of BRAF-targeted therapy for advanced melanoma in the immunotherapy era. Curr Oncol Rep 21(9):76. https:\/\/doi.org\/10.1007\/s11912-019-0827-x","journal-title":"Curr Oncol Rep"},{"issue":"1A","key":"17_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5114\/wo.2018.73890","volume":"22","author":"J Mackiewicz","year":"2018","unstructured":"Mackiewicz J, Mackiewicz A (2018) BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. Contemp Oncol (Pozn) 22(1A):68\u201372. https:\/\/doi.org\/10.5114\/wo.2018.73890","journal-title":"Contemp Oncol (Pozn)"},{"key":"17_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10582","volume":"7","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM (2016) Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy. Nat Commun 7:10582. https:\/\/doi.org\/10.1038\/ncomms10582","journal-title":"Nat Commun"},{"issue":"7","key":"17_CR22","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/jid.2012.63","volume":"132","author":"K Gowrishankar","year":"2012","unstructured":"Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H (2012) Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF\/MEK inhibition. J Invest Dermatol 132(7):1850\u20131859. https:\/\/doi.org\/10.1038\/jid.2012.63","journal-title":"J Invest Dermatol"},{"issue":"5","key":"17_CR23","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1080\/15384047.2015.1026507","volume":"16","author":"EJ Wyluda","year":"2015","unstructured":"Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, Drabick JJ (2015) Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biol Ther 16(5):662\u2013670. https:\/\/doi.org\/10.1080\/15384047.2015.1026507","journal-title":"Cancer Biol Ther"},{"key":"17_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/ITT.S134842","volume":"7","author":"B Domingues","year":"2018","unstructured":"Domingues B, Lopes JM, Soares P, Populo H (2018) Melanoma treatment in review. Immunotargets Ther 7:35\u201349. https:\/\/doi.org\/10.2147\/ITT.S134842","journal-title":"Immunotargets Ther"},{"issue":"29","key":"17_CR25","doi-asserted-by":"publisher","first-page":"48507","DOI":"10.18632\/oncotarget.17397","volume":"8","author":"D Quandt","year":"2017","unstructured":"Quandt D, Dieter Zucht H, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M, Lambrechts D, Oberacher H, Garrett J, Nayak T, Kazinski M, Massie C, Schwarzenbach H, Maio M, Prins R, Wendik B, Hockett R, Enderle D, Noerholm M, Hendriks H, Zwierzina H, Seliger B (2017) Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget 8(29):48507\u201348520. https:\/\/doi.org\/10.18632\/oncotarget.17397","journal-title":"Oncotarget"},{"issue":"3","key":"17_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19(3):133\u2013150. https:\/\/doi.org\/10.1038\/s41568-019-0116-x","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"17_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.14740\/jocmr3750","volume":"11","author":"R Bajwa","year":"2019","unstructured":"Bajwa R, Cheema A, Khan T, Amirpour A, Paul A, Chaughtai S, Patel S, Patel T, Bramson J, Gupta V, Levitt M, Asif A, Hossain MA (2019) Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic t-lymphocyte-associated protein-4 inhibitors): results of a retrospective study. J Clin Med Res 11(4):225\u2013236. https:\/\/doi.org\/10.14740\/jocmr3750","journal-title":"J Clin Med Res"},{"issue":"1","key":"17_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG (2019) The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer 7(1):278. https:\/\/doi.org\/10.1186\/s40425-019-0768-9","journal-title":"J Immunother Cancer"},{"key":"17_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.critrevonc.2017.06.001","volume":"116","author":"S Maleki Vareki","year":"2017","unstructured":"Maleki Vareki S, Garrigos C, Duran I (2017) Biomarkers of response to PD-1\/PD-L1 inhibition. Crit Rev Oncol Hematol 116:116\u2013124. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.06.001","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"17_CR30","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17(12):e542\u2013e551. https:\/\/doi.org\/10.1016\/S1470-2045(16)30406-5","journal-title":"Lancet Oncol"},{"issue":"3","key":"17_CR31","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ejso.2016.07.014","volume":"43","author":"D Kee","year":"2017","unstructured":"Kee D, McArthur G (2017) Immunotherapy of melanoma. Eur J Surg Oncol 43(3):594\u2013603. https:\/\/doi.org\/10.1016\/j.ejso.2016.07.014","journal-title":"Eur J Surg Oncol"},{"issue":"7528","key":"17_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563\u2013567. https:\/\/doi.org\/10.1038\/nature14011","journal-title":"Nature"},{"key":"17_CR33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/1479-5876-10-192","volume":"10","author":"JB Freeman","year":"2012","unstructured":"Freeman JB, Gray ES, Millward M, Pearce R, Ziman M (2012) Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. J Transl Med 10:192. https:\/\/doi.org\/10.1186\/1479-5876-10-192","journal-title":"J Transl Med"},{"issue":"16","key":"17_CR34","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1158\/1078-0432.CCR-16-1821","volume":"23","author":"JC Sunshine","year":"2017","unstructured":"Sunshine JC, Nguyen PL, Kaunitz GJ, Cottrell TR, Berry S, Esandrio J, Xu H, Ogurtsova A, Bleich KB, Cornish TC, Lipson EJ, Anders RA, Taube JM (2017) PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison. Clin Cancer Res 23(16):4938\u20134944. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1821","journal-title":"Clin Cancer Res"},{"issue":"9","key":"17_CR35","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","volume":"97","author":"GJ Kaunitz","year":"2017","unstructured":"Kaunitz GJ, Cottrell TR, Lilo M, Muthappan V, Esandrio J, Berry S, Xu H, Ogurtsova A, Anders RA, Fischer AH, Kraft S, Gerstenblith MR, Thompson CL, Honda K, Cuda JD, Eberhart CG, Handa JT, Lipson EJ, Taube JM (2017) Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab Investig 97(9):1063\u20131071. https:\/\/doi.org\/10.1038\/labinvest.2017.64","journal-title":"Lab Investig"},{"issue":"2","key":"17_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/PAI.0000000000000531","volume":"26","author":"ER Parra","year":"2018","unstructured":"Parra ER, Villalobos P, Mino B, Rodriguez-Canales J (2018) Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on non-small cell lung carcinoma. Appl Immunohistochem Mol Morphol 26(2):83\u201393. https:\/\/doi.org\/10.1097\/PAI.0000000000000531","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"17_CR37","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1186\/s12885-016-2758-3","volume":"16","author":"A Anantharaman","year":"2016","unstructured":"Anantharaman A, Friedlander T, Lu D, Krupa R, Premasekharan G, Hough J, Edwards M, Paz R, Lindquist K, Graf R, Jendrisak A, Louw J, Dugan L, Baird S, Wang Y, Dittamore R, Paris PL (2016) Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer 16(1):744. https:\/\/doi.org\/10.1186\/s12885-016-2758-3","journal-title":"BMC Cancer"},{"issue":"1","key":"17_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","volume":"109","author":"K Mimura","year":"2018","unstructured":"Mimura K, Teh JL, Okayama H, Shiraishi K, Kua LF, Koh V, Smoot DT, Ashktorab H, Oike T, Suzuki Y, Fazreen Z, Asuncion BR, Shabbir A, Yong WP, So J, Soong R, Kono K (2018) PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci 109(1):43\u201353. https:\/\/doi.org\/10.1111\/cas.13424","journal-title":"Cancer Sci"},{"key":"17_CR39","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","volume":"9","author":"F Castro","year":"2018","unstructured":"Castro F, Cardoso AP, Goncalves RM, Serre K, Oliveira MJ (2018) Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol 9:847. https:\/\/doi.org\/10.3389\/fimmu.2018.00847","journal-title":"Front Immunol"},{"issue":"2","key":"17_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211866","volume":"14","author":"JW Po","year":"2019","unstructured":"Po JW, Ma Y, Balakrishna B, Brungs D, Azimi F, de Souza P, Becker TM (2019) Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status. PLoS One 14(2):e0211866. https:\/\/doi.org\/10.1371\/journal.pone.0211866","journal-title":"PLoS One"}],"container-title":["Methods in Molecular Biology","Melanoma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-1205-7_17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T12:07:34Z","timestamp":1615464454000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-0716-1205-7_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9781071612040","9781071612057"],"references-count":40,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-1205-7_17","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"12 March 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}